If You Cannot Win Them, Join Them: Understanding New Ways to Target STAT3 by Small Molecules by Sabanes Zariquiey F et al.
If You Cannot Win Them, Join Them: Understanding New Ways to
Target STAT3 by Small Molecules
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ABSTRACT: Signal transducer activator of transcription 3
(STAT3) is among the most investigated oncogenic tran-
scription factors, as it is highly associated with cancer initiation,
progression, metastasis, chemoresistance, and immune evasion.
Evidences from both preclinical and clinical studies have
demonstrated that STAT3 plays a critical role in several
malignancies associated with poor prognosis such as
glioblastoma and triple-negative breast cancer, and STAT3
inhibitors have shown efficacy in inhibiting cancer growth and
metastasis. Constitutive activation of STAT3 by mutations
occurs frequently in tumor cells and directly contributes to
many malignant phenotypes. Unfortunately, detailed structural
biology studies on STAT3 as well as target-based drug
discovery efforts have been hampered by difficulties in the expression and purification of the full-length STAT3 and a lack
of ligand-bound crystal structures. Considering these, molecular modeling and simulations offer an attractive strategy for the
assessment of the “druggability” of STAT3 dimers and allow investigations of reported activating and inhibiting STAT3 mutants
at the atomistic level of detail. In the present study, we focused on the effects exerted by reported STAT3 mutations on the
protein structure, dynamics, DNA-binding, and dimerization, thus linking structure, dynamics, energetics, and the biological
function. By employing atomistic molecular dynamics and umbrella-sampling simulations to a series of human STAT3 dimers,
which comprised wild-type protein and four mutations, we explained the modulation of STAT3 activity by these mutations.
Counter-intuitively, our results show that the D570K inhibitory mutation exerts its effect by enhancing rather than weakening
STAT3−DNA interactions, which interfere with the DNA release by the protein dimer and thus inhibit STAT3 function as a
transcription factor. We mapped the binding site and characterized the binding mode of a clinical candidate napabucasin/BBI-
608 at STAT3, which resembles the effect of a D570K mutation. Our results contribute to understanding the activation/
inhibition mechanism of STAT3, to explain the molecular mechanism of STAT3 inhibition by BBI-608. Alongside the
characterization of the BBI-608 binding mode, we also discovered a novel binding site amenable to bind small-molecule ligands,
which may pave the way to design novel STAT3 inhibitors and to suggest new strategies for pharmacological interventions to
combat cancers associated with poor prognosis.
■ INTRODUCTION
Signal transducer activator of transcription 3 (STAT3) protein
has emerged as a prominent target in tumor progression due to
its pivotal role in cell signaling.1 The activation of the STAT3
protein has been also related to drug resistance,2 to the
expression of other anti-apoptotic proteins,3 and to the
inflammatory processes in tumor development, among
others.4−6 Despite its importance in cancer progression, the
pharmacological drugging of STAT3 is still a challenge that
demands clarification. Its tendency to aggregate is amajor hurdle
that prevents the determination of the structure in both
monomeric and dimeric forms as well as bound to small-
molecule inhibitors.7−9 Although many strategies have been
described in the literature to inhibit STAT3, only a few
inhibitors are still going through clinical trials (e.g., TTI-101
[ClinicalTrials.gov Identifier: NCT03195699] or napabucasin
(BB I - 6 08 ) 1 0− 1 2 [C l i n i c a lT r i a l s . g o v I d e n t ifi e r :
NCT03647839]), and STAT3 has become one of the most
challenging cancer-related proteins to target by small molecules.
Gaining insights into the atomistic-level characteristics of
STAT3 would permit the identification of novel strategies to
interact with this protein by small molecules and target
oncogenic pathways indirectly. The human STAT3 monomer
is composed of six highly specialized domains (i.e., N-terminal,
coiled-coil domain, DNA-binding domain, linker domain, SH2
domain, and C-terminal transactivation domain). Particularly,
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the DNA-binding domain (residues: 320−494) is responsible
for the DNA-binding when STAT3 is in the dimeric form. An α-
helix linker domain joins the latter with the SH2 domain, which
is essential for the binding of STAT3 to phosphorylated
receptors and for its dimerization (residues: 493−583). This
process is mainly facilitated by the SH2 domain, as each
monomer interacts after the phosphorylation of a specific
tyrosine residue (Y705) located in the transactivation
domain.13,14 Therefore, in an attempt to avoid the dimerization,
the SH2 domain has traditionally been the main target for drug
design, mostly accompanied by computational studies relying on
molecular docking calculations or similar structure-based
approaches,15−23 despite no crystallographic data being
available up to date to support them. These ligands attempt to
compete with phosphorylated p-Y705 at the site known to
recognize phosphorylated residues24,25 with limited success. An
alternative, represented by OPB-3112126 and OPB-51602,4 is to
target an allosteric site at the SH2 domain: these compounds
bind to a pocket different from the one binding p-Y705.4,26
Furthermore, STAT3 can undergo other post-translational
modifications besides Y705 phosphorylation, such as S727
phosphorylation,13,27 and it has been experimentally demon-
strated that unphosphorylated STAT3 can dimerize and bind to
DNA. This provides an alternative strategy to targeting the SH2
domain directly. Due to the challenges coupled with the effective
targeting of STAT3 SH2 domains, other STAT3 domains have
thus been explored in the development of potent and selective
STAT3 inhibitors. Recently, several inhibitors have been
identified to bind to the DNA-binding domain (DBD), which
has been initially overlooked due to its potential specificity
problems. Experimental evidence shows that its binding by small
molecules permits the dimer formation, whereas disrupts the
DNA−protein binding.28−30 The exploration through alter-
natives to the SH2 domain might be the key to unlock the
STAT3 “druggability” problem. The conservation of the three-
dimensional structure of the whole protein is crucial for the
activity of STAT3. Experimental data have demonstrated that
point mutations in the linker domain suggest contacts with both
the DNA-binding and SH2 domains, which could cause
structural changes that severely affect STAT3 activity.31 Alanine
scanning demonstrated that the modification of interdomain
hydrogen bonds can produce a significant decrease (i.e., K551A,
W546A) or increase (D570K) in the STAT3−DNA-binding
compared to that in the wild-type protein.31 Understanding the
effect of point mutations on STAT3 activity at the atomistic level
could provide significant information about novel binding sites,
unveiling new ways to target STAT3 by small-molecule ligands.
The lack of a ligand-bound crystallized structure hinders the
path for an effective structure-based ligand design for both
computational and medicinal chemists. Only a few moderate-
resolution crystal structures of mouse STAT3 (PDB id: 1BG1,9
3CWG,7 and 4E688) are available, and none of them present a
bound ligand. A small number of STAT3 inhibitors are under
clinical trials, but in most cases their binding sites at STAT3 and
hence their binding modes remain unknown. Among them,
napabucasin (BBI-608) is a first-in-class cancer stemness
inhibitor that targets STAT3,12 which is being tested (phase
3) as a treatment in advanced colorectal cancer.11 Ji and co-
workers reported that napabucasin binds in a pocket between
the linker and the DNA-binding domain in a STAT3 crystal
structure,32 but the crystal structure has not been disclosed.
In this study, we addressed the druggability of the STAT3
dimer at the atomistic level of detail by performing equilibrium
all-atom molecular dynamics (MD) and umbrella-sampling
(US) simulations to determine the behavior of the wild-type and
mutated STAT3. Monitoring the time evolution of the different
domains at a time scale of hundreds of nanosceconds revealed
their differential behaviors in terms of molecular flexibility and
their ability to bind DNA when point mutations were
introduced. The examination of mutation-induced structural
changes directed us to new sites amenable to inhibition by small-
molecule ligands. Furthermore, the construction of a homology
model of ligand-bound STAT3 along with MD and US
simulations helped us understand the behavior of a ligand that
interacts with a newly identified “druggable” region of STAT3.
Since this study focuses on the DBD and its interaction with
DNA, we took special interest in Husby’s previous work, which
investigated the interaction between STAT3 and DNA.33
■ RESULTS AND DISCUSSION
Mutations Directly Affect the Sampled Configurations
of the STAT3 Dimer. In the study by Mertens and co-workers,
several mutations were indicated as crucial to control the DNA
retention time within its respective binding cleft at STAT3.31
These mutations occurred either in the DNA-binding domain or
in the interdomain region. Prior to the US simulations to
Figure 1. View of the mutated residues that form interdomain interactions and affect STAT3 (PDB code 1BG1) behavior, particularly DNA-binding.
SH2 domain (cyan), linker domain (orange), DNA-binding domain (red), and DNA (blue) are highlighted. Side-chains of the target residues are
displayed as gray sticks.
ACS Omega Article
DOI: 10.1021/acsomega.9b01601
ACS Omega 2019, 4, 13913−13921
13914
evaluate the DNA-binding in the mutated systems, a series of 50
ns MD simulations are performed to equilibrate the system and
identify different behaviors of the studied systems with regard to
the WT. Systems have been studied for the amount of time that
Husby’s work claims to be necessary to achieve an energetically
conserved and stable simulation.33 Our results agree with those
of Husby, as we could observe how one of the proteinmonomers
is more flexible than the other and that root-mean-square
deviation (RMSD) variations are mainly capitalized by the loops
of SH2 and the coiled-coil domains.
One of the most significant configurational changes occurred
within the D570K mutant, as the DNA double helix shifted
downward (Figure 2). This was most likely caused by the
electrostatic effects at the residue located in the interface
between the linker and the DNA-binding domain. The
modification of the side-chain charge from negative (D) to
positive (K) increased favorable protein interaction with the
negatively charged nucleic backbone. This tightened the DNA-
binding, resulting in a higher average DNA RMSD when
compared to that of the crystal structure. It strongly indicates
that the end-point configurations of the protein−DNA
complexes play a significant role in their binding free energy,
since the protein−nucleotide interactions change significantly
between different mutants.
We assessed whether the conformational changes induced by
the D570Kmutation were observed in other mutations. Figure 3
shows root-mean-square deviation (RMSD) plots of all STAT3
considered in this study as well as the WT protein. Except
D570K, there were no large differences in protein RMSDs
between the mutated STAT3 dimers andWT. This gap between
D570K and other mutants is likely to arise from the combination
of electrostatic and steric effects (all other mutations replaced
large and polar residues with the smaller and apolar alanine),
which affect the intrinsic dynamics of the coiled-coil (CC)
domain. Hence, the dynamics of the CC domain might “tune”
DNA−STAT3 interactions by allowing adjacent SH2 and DBD
domains to improve their structural “fit” to the DNA.
To follow up on the effects of the mutations that control DNA
retention at the STAT3 on the structure, dynamics, and
energetics of STAT3−DNA complexes, we carried out a set of
umbrella-sampling (US) simulations, where DNA has been
pulled from the STAT3 dimer. This process was studied using a
series of US windows and simulated for 10 ns each.
The potential of mean force (PMF) calculated via the
weighted histogram analysis method (WHAM) was consistent
with the results reported by Mertens and co-workers31 in most
cases. Experimental results showed a drop in the DNA-binding
for the tested interdomain mutations (EE434/435AA, W546A,
and K551A) through time and an extraordinarily high retention
time for D570K, with 100% DNA-binding even after 2 h.31 The
WT STAT3 had a higher energy barrier to reach its unbound
state in comparison to the W546A mutant (Table 1). The
mutant shows a lower retention time, which indicates that
interdomain interactions between mutated residues and E434
are crucial for STAT3−DNA-binding. Therefore, disrupting
these interactions could represent an attractive strategy to target
STAT3 by small molecules. K551A shows a profile similar to
that of D570K, but presents a PMF value lower than that of the
mutation and a few kcal/molmore than that of theWT (Figure 4
and Table 1).
The equilibrium MD simulations as well as PMF showed that
the binding affinity of D570K to DNA is more favorable than
that of any other mutant and more than that of WT STAT3
(Figure 4). This indicates that this mutation promotes a tight
binding between STAT3 and DNA, with a higher energy gap for
DNA release upon pulling. The PMF curve showed that DNA-
pulling from D570K required a higher energy gap to release the
DNA from the STAT3 dimer. The experimental retention time
correlated with the simulations when compared to WT STAT3.
The data showed that DNA-binding to D570K was persistent
through time, did not drive transcription, and resisted
dephosphorylation, and thus prevented STAT3 from exerting
its function.12
Collectively, these results indicate that D570K promotes a
tight DNA-binding, so much that the bound duplex stays
“locked” between the dimers, which effectively inhibits STAT3
by preventing it from releasing DNA and exerting its function as
a transcription factor.
The major discrepancy between our simulations and
experimental data was observed for the EE434/435AA double
mutant. In the simulations, the mutant showed a higher PMF
value than the WT, which indicated that its DNA-binding
affinity should be higher, whereas experimental data showed that
its behavior resembled that of the W546A mutant, which has
shown a considerable drop of DNA-binding through time.
Analysis of the final US windows indicated that the middle of the
DNA duplex interacted favorably with the DNA-binding
domain of one STAT3 monomer, but not another. Therefore,
the US curve of the EE434435AA mutant displayed higher
values arising from these interactions (DNA−STAT3 mono-
Figure 2. MD simulations show conformational changes between WT
(blue) and D570K (red) STAT3 dimer systems. In the D570K mutant,
one of the monomers is shifted (panel A to panel B), changing the
conformational landscape of the dimer. Panel C shows how the position
of the DNA duplex is shifted downward in the D570K mutant
compared to the WT.
ACS Omega Article
DOI: 10.1021/acsomega.9b01601
ACS Omega 2019, 4, 13913−13921
13915
mer) rather than from favorable interactions of the DNA−
STAT3 dimer, as was the case with the D570K mutant.
Mertens’ results31 are based on 60 to 100 min experiments
that evaluate the percentage of DNA-binding of STAT3. This
process would include several STAT3 molecules that would
most likely go through several mechanistic cycles. Therefore, it is
plausible that we did not sample the conformations that are
contributing to these results.
Arginine R414 Acts as a “Gatekeeper” for DNA-
Binding. All simulations indicated significant conformational
changes of the arginine R414, which were required to release
DNA (or to allow the DNA-binding to the STAT3 dimer). R414
has been shown previously as one of the main residues for DNA
identification and binding,33 but was not disclosed as a
gatekeeper residue. It is at a close distance from the DNA, and
its initial position did not allow the DNA to exit from the dimer.
By acting as a gatekeeper of DNA-binding, R414 exerted a key
role in controlling the opening and closing of the STAT3 dimer
as well as tuned the dynamics of STAT3 monomers by
modulating intradomain DBD−SH2, CC−SH2, DBD−LD, and
CC−LD interactions.(Figure 5)
Inhibition of STAT3 by Napabucasin (BBI-608). The
results of simulations of apoSTAT3 (WT and mutants)
highlighted a set of interdomain residues, explaining their effect
on STAT3 behavior and function at the atomistic level of detail.
These observations may pave the way to novel strategies for
STAT3 inhibition using small-molecule ligands. Traditionally,
the structure-guided ligand design for STAT3 inhibition focused
on targeting the SH2 domain, which intended to prevent STAT3
dimerization. Although several inhibitors have been described to
bind to the SH2 domain,18,34−38 there is no crystal structure
available to confirm it, and most studies focusing on the SH2
Figure 3. Protein (A) and DNA (B) RMSDs after 50 ns of MD simulation. The D570K (blue) mutation shows a higher RMSD in both protein and
DNA counterparts compared to the other mutations and WT-STAT3.
Table 1. Free Energy Change Calculated via US for all US
Calculations
run ΔGUS (kcal/mol)
WT −42.6 ± 2
EE43435AA −62.7 ± 2
W546A −35.7 ± 2
K551A −58.7 ± 1
D570K −58.5 ± 1
BBI-608 −127.0 ± 1
Figure 4. Potential of mean force (PMF) of dissociation of DNA from
the STAT3 dimer. The W546A (purple) mutant shows a lower PMF
than theWT (violet), whereas the PMF of K551A (brown) mutant is in
the same range as that of the WT. Both EE434435AA (green) and
D570K (marine green) would have displayed similar results, but the
interaction between the DNA duplex and DBD of one STAT3
monomer resulted in higher PMF values than expected in later sampling
windows. This indicates that DNA−protein interactions are more
favorable in these mutants relative to the WT. The BBI-608 binding
(blue) showed a trend similar to that of EE434435AA and D570K
mutations, but much more pronounced.
Figure 5. Conformational changes of arginine R414 observed during
our simulations. Evolution of the DNA duplex and R414 position over
the simulation time is depicted by colors, from red to white. Along the
DNA-pulling pathway from the STAT3 dimer, the R414 side-chain
rotates, allowing the dissociation to occur.
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domain binders relied mainly on semi-rigid molecular-docking
calculations, whichmay raise the question as to whether the SH2
domain is the binding site for their studied molecules. A few
inhibitors such as OPB-31121 and OPB-51602 proved their
binding to an allosteric site in the SH2 domain via mutagenesis
analysis,26 giving some insight into an alternative pocket to study
the SH2-mediated inhibition. Additionally, there are reports of a
few inhibitors that target DBD. Their binding modes have been
virtually assessed, but again, these studies rely heavily on
molecular docking.28−30
Recently, Ji and co-workers reported that napabucasin (BBI-
608), which is one of the few STAT3 inhibitors in advanced
clinical trials (phase 3), binds to a small pocket between the
linker and the DNA-binding domain in a STAT3 crystal
structure.32 Since the crystal structure has not been released to
the public domain, we have assessed the druggability of this
segment of STAT3, identified the putative pocket, and
subsequently built the model of BBI-608 bound to STAT3
using the molecular-docking approach, and then validated the
obtained binding mode by the atomistic MD and US
simulations.
Molecular docking was performed by MOE for each STAT3
monomer separately, trying to generate the most plausible
conformation relying on the limited data available. Both blind
(whole monomer) and targeted (residues of the identified
pocket) docking calculations resulted in a set of conformations
with favorable energy scores and a highly populated cluster
located within the DBD site pocket, in close contact with
residues H332, P333, R335, K573, and D570 (Figure 6). Two
conformations, matching the published data, were found; both
were assessed and validated.
To validate the binding mode of BBI-608, MD simulations of
the WT STAT3−DNA−BBI-608 complex were performed for
100 ns in triplicate. Subsequently, the ligand affinity has been
calculated. The ligand docked on either of the SAT3 monomers
remained bound through the whole simulation. Interaction
energies calculated by MMPBSA analysis (g_mmpbsa39
module) resulted in −18.1 ± 2.6 kcal/mol, showing a favorable
binding.
US simulations, performed using the same protocol as for
STAT3−DNA complexes, started the pull from the most
populated cluster. The calculated binding affinity has been
overestimated (−160 kcal/mol); nevertheless, it showed a very
tight binding. Compared with the results obtained for protein−
DNA complexes described in the previous section, it implies that
the presence of BBI-608 enhances DNA-binding with an effect
similar to that of the D570Kmutation. As such, BBI-608 inhibits
the function of STAT3 in a manner similar to the D570K
mutation, which does not drive transcription and resists
phosphorylation.12 Since D570 has been annotated by Ji et
al.32 as the BBI-608-binding-site residue, we concluded that BBI-
608 binding to WT STAT3 generated a DNA−protein
interaction pattern and retention time similar to that of the
D570K mutation.
BBI-608 Binding Promotes STAT3 Dimerization. We
performed MD simulations of the BBI-608-bound WT STAT3
dimer without DNA to study the influence of the ligand on the
protein behavior in the absence of DNA. BBI-608 was bound to
each STAT3 monomer, and four 100 ns replicas showed a
variation of results. In only one out of the four replicas, both BBI-
608 molecules remained bound in their pockets through the
whole trajectory, whereas DBD domains of both STAT3
monomers moved closer to each other, reaching the point of
forming interdomain hydrogen bonds. In one simulation, both
ligand molecules dissociated from the pockets, which caused an
opening of the STAT3 dimer, and in the other two, only one of
the ligands left the binding cavity at the 35 and 70 ns marks.
To assess ligand-induced conformational changes within the
DNA entry through both DBD domains, distances between
some of the residues involved in H-bonding (e.g., Q344-G342
andT412-Q344) weremeasured and analyzed in all four replicas
and compared to the simulation of the WT STAT3 dimer
without DNA and/or BBI-608 bound (Figure 7).
The STAT3 dimer closed further down in the presence of
BBI-608. This was particularly pronounced in one of the
replicas, in which the distance between monomers reduced to
<5 Å. These results indicate that BBI-608 binding to apoSTAT3
is likely to trigger conformation changes that would prevent
DNA from binding. In the replica simulation, where both ligands
dissociated from STAT3, the distance between monomers
increased upon ligand dissociation, as both ligands exit via the
gap formed between DBD domains of STAT3 monomers.
The protein−ligand interaction energy was calculated, and a
correlation between ligand dissociation, dimer separation, and
poor ligand affinity could be observed.
The simulations also indicate that the ligand binding to one of
the STAT3 monomers is more favorable than it binding to
another one. Although interaction energies are favorable for
both monomers, one shows an interaction energy value twice as
favorable as for another monomer. Although the allosteric
effects within STAT3 were beyond the scope of this study, these
results strongly suggest that such effects may occur in STAT3
dimers and contribute to the modulation of STAT3 by
inhibitors. Another theory could be that the model is not as
optimal as expected. Although the used docking poses have an
extraordinary resemblance to Ji’s data,32 only one is shown in the
patent. Since this dimer is asymmetrical, DNA interactions with
both cavities will be different and could imply a different
conformation and/or location for the ligand that does not
correspond to the model one. Furthermore, the MD results
strongly indicate that one monomer is much more mobile than
the other, and this is likely to affect protein−ligand affinity
fluctuations.
Identification of a Novel Druggable Binding Site.
Experimental results12 combined with the simulations strongly
indicated that targeting the interface between STAT3
monomers may trigger a response similar to the inhibition by
Figure 6. Binding pose of BBI-608, deduced from the data reported by
Ji and co-workers.32 Since the crystal structure has not been released, we
have modeled the most plausible binding mode by molecular docking.
The side-chain of the mutated K570 residue is displayed and colored
green; it is overlapping with the plausible location of BBI-608.
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ligands binding to the DBD domain, and therefore must be
explored in structure-based ligand design efforts. With most
STAT3 ligands being designed for the SH2 domain and just a
few for the DBD domain, the identification of new druggable
pockets for STAT3 inhibition is of great interest.
As such, we scanned STAT3 for the presence of potential
binding sites with two pocket detection tools: fpocket40 and
MOE’s Site Finder. Upon selection of the dimer model and
different clusters from its MD simulation trajectories, we
confirmed the binding site identified for BBI-608,32 which has
been identified by both tools as their top-ranked site.
Interestingly, this site was detected by both fpocket and
SiteFinder for all analyzed structures (Figure 8). In addition, a
new pocket within the DNA-binding domain (in close contact
with E434 and E435) was identified. The main difference
between results obtained by both tools is that fpocket was more
prone to detect SH2 domain sites as pockets (Figure 8, B2-3),
whereas SiteFinder identified a novel druggable pocket close to
R414 (Figure 8, A1). Ligand binding to the R414 pocket could
result in a possible DNA-release/binding impediment.
■ CONCLUSIONS
The use of computational approaches based on atomistic
molecular dynamics simulations enabled us to understand the
effects of specific STAT3mutations, which were described in the
literature, and to explain their modulation of the STAT3 activity.
Consistent with the findings of Mertens and co-workers,32
D570K mutation exerted its effect by enhancing interactions
between STAT3 and DNA, which interfered with DNA release
by the STAT3 dimer and thus inhibited the protein’s function by
Figure 7. (A) Interatomic distances between the Cα of residues Q344 and G432 and residues T412 andQ344, calculated along a 50 nsMD simulation
of ligand−STAT3 complexes. Replica 1 (blue) consists of the dissociated system and both Replicas 2 and 3 (orange and green) keep their ligand bound
through the whole simulation. (B) Close-up and (C) panoramic views as the STAT3 dimer closes once the BBI-608 molecule is bound. (D) Protein−
ligand energy interaction for both BBI-608 molecules interacting with each monomer along a 50 ns MD simulation (three replicas: blue, red, and
green). The STAT3 dimer bound to DNA (black) is shown as the reference.
Figure 8.Druggability of the STAT3 dimer. Sitefinder (A) and fpocket (B) were used to identify new potential pockets for structure-based drug design.
In both cases the BBI-608 DBD site was identified along with novel DBD pockets.
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not driving transcription and resisting dephosphorylation.
Subsequently, recent identification of a plausible binding site
for the small-molecule STAT3 inhibitor nababucasin (BBI-608)
helped us to deconvolute its inhibition mechanism, which
resembled the effect exerted by the D570K mutation. The
identification of the putative binding site for BBI-608 at the
DNA-binding domain may contribute to the development of
novel potent and selective STAT3 inhibitors. The similarity
between the model and the available patent data32 raise the
question as to why this pocket has been overlooked before.
Mutated interdomain residues E435, W546, and K551 unveil a
poor binding to DNA, leading to yet another way of targeting
STAT3 by disrupting theses residues, pointing toward possible
novel allosteric binding sites. Structure-based ligand designs
targeting these novel pockets, coupled with novel method-
ologies, such as employing the recently developed FragLites,41
are likely to expand a set of chemotypes active toward STAT3
and contribute to the development of novel inhibitors of this
important yet very challenging drug target.
■ METHODS
MolecularModeling of theHuman STAT3Dimer. Initial
models of dimeric human STAT3 (wild type and mutants) in a
complex with DNA were created using the crystal structure of
unphosphorylated mouse STAT3B (PDB code: 4E68), which
spans residues 136−716. The N-terminal domain has been
excluded from the structures subjected to the simulations. Loops
spanning the residues 184−194 and 688−702 were modeled
using the MODELLER interface42,43 available in UCSF
Chimera.44 The DNA double-strand bound to the model was
designed based on 4E68, with the 5′−3′ strand sequence of
TGCATTTCCCGTAATC. The final model was subjected to
20 000 cycles of the steepest descent energy minimization.
The STAT3 mutations (Figure 1), which were selected
following the study by Mertens and co-workers,31 were
introduced in UCSF Chimera by swapping side-chains to the
target residues and adjusting new conformations using
Dunbrack’s rotamer library integrated within UCSF Chimera.
Modeling of Ligand-Bound STAT3. The crystal structure
of ligand-bound STAT3 is not yet available; therefore, we built
the most similar model possible with the accessible data. Starting
from the dimer model of wild-type STAT3 described in the
previous section, molecular-docking calculations were per-
formed with MOE,45 using napabucasin (BBI-608) as the
ligand. To ensure the scoring function accuracy with the target
and the best possible fit, both blind (full dimer, residues 136−
716) and targeted docking (pocket described) were performed.
Two hundred different conformations of the ligand were scored
for each run using TriangleMatcher and LondonΔG for the first
scoring function. Thereafter, the top 100 conformations were
rescored using Induced Fit and the generalized Born volume
integral/weighted surface area score.45 From the final poses
obtained, one for each monomer was selected based on the
score, interactions, and consistency with the experimental
structure shown in Ji’s work,32 which shows BB1-608 bound
to a pocket located within the DNA−STAT3 interface.
Molecular Dynamics and Umbrella-Sampling Simu-
lations.To study the effects of the dynamics of mutations in the
STAT3 dimer, each of the listed mutations was created in UCSF
Chimera.44 Structural hydrogens were added and the following
protein parametrization was performed using the Gromacs
2016.0346 suite with AMBERFF99SB-ILDN47 force field.
Before pulling the DNA from the complex, the systems were
relaxed with a short equilibriumMD production run. Hence, a 1
nm cubic box was centered on the structure and the system is
solvated with TIP3P waters. Sodium and chloride ions were
added to a concentration of 0.1 M, resulting in systems with
more than seven hundred thousand atoms. Bonds were
constrained using the LINCS48 algorithm. The electrostatic
interactions were calculated using the particle-mesh Ewald
method, with a nonbonded cut-off set at 0.1 nm. All structures
were minimized via the steepest descent algorithm for 20 000
steps of 0.02 nm, and minimizations were stopped when the
maximum force fell below 1000 kJ/(mol nm) using the Verlet
cut-off scheme.49 After minimization, temperature equilibration
was performed for 100 ps with a time step of 2 fs with position
restraints applied to the backbone using an NVT. The
temperature coupling was set between the protein and the
nonprotein entities by using a Berendsen thermostat,50 with a
time constant of 0.1 ps, and the temperature set to reach 300 K
with the pressure coupling off. Sequentially, a pressure NPT
equilibration was performed, followed by 100 ps of NVT
equilibration, 100 ps of NPT equilibration, and a production run
of 100 ns. The temperature was set constant at 300 K by using a
modified Berendsen thermostat (τ = 0.1 ps).50 The pressure was
kept constant at 1 bar by Parinello−Rahman isotropic coupling
(τ = 2.0 ps) to a pressure bath.51
For the umbrella-sampling simulation, a 50 ns pre-umbrella
equilibration was carried out, with the complex rotating its
principal axis to align with the z-axis of the simulation box. A pull
sampling was performed using a constant force approach (k =
1000 kJ/(mol nm), with a rate of 0.01 nm) between the centers
of masses of the SH2 domain and the DNA double helix, along
the described path shown in Figure 9. From each corresponding
pull simulation, a series of conformations have been selected to
sample the process of entering−exiting the DNA-binding site.
Each of the 25 selected umbrella windows has been through a 1
Figure 9. Description of the STAT3 umbrella-sampling (US)
simulations performed in this study. After 100 ns of equilibrium MD
production run, DNA is pulled out of the dimer and a series of windows
are selected that will be simulated for 10 ns to compute the potential of
mean force (PMF) of DNA.
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ns NPT equilibration run, followed by a 5 ns NPT distance-
restrained production run, totalizing per system 135 ns of
simulation time, using the previously described protocol and
parameters. Afterward, the potential of mean force (PMF) curve
of the studied scenario has been calculated with the weighted
histogram analysis method (WHAM) tool from Gromacs,52 and
associated errors were calculated using both the convergence
criteria and the implemented bootstrap method in Gromacs
WHAM. All calculations for the analysis were made using the
Gromacs tools.
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